摘要
胃肠道(GI)肿瘤是全球癌症患者死亡的主要原因之一。特别是,胃癌(GC)是癌症死亡的第三个原因,而食管肿瘤是全球第八大主要癌症,其发病率尤其是腺癌类型在不断增加。此外,肝细胞癌,胆管癌和胰腺癌是多学科方法的一个非常有趣的模型,最近新药被用于治疗。目前,新的临床试验被设计成包括与小分子抑制剂(即酪氨酸激酶抑制剂)和/或单克隆抗体(即抗EGFR抗体)联合的经典化疗。此外,这个问题还包括一个用于靶向治疗的新分子的综合列表。新的治疗模式(多学科方法)和靶向治疗方法的发展有助于改善这些癌症疾病的结果。在过去几年中,恶性肿瘤的分子生物学,特异性靶点的发现以及由此产生的阻断关键激酶和几种分子途径的全身性药物的开发都取得了令人瞩目的进展,这些都促进了癌症治疗的进展,同样在GI非结直肠癌癌症治疗。
关键词: 胃肠癌,目标疗法,临床方面,治疗,预后因素,转移,费用
图形摘要
Current Cancer Drug Targets
Title:The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Volume: 18 Issue: 5
关键词: 胃肠癌,目标疗法,临床方面,治疗,预后因素,转移,费用
摘要: Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome in these cancer diseases. During the past few years, remarkable progress in molecular biology of malignancy, the discovery of specific targets, and the resulting development of systemic drugs that block critical kinases and several molecular pathways have all contributed to progress in cancer treatment, also in GI non-colorectal cancer treatment.
Export Options
About this article
Cite this article as:
The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170208162058
DOI https://dx.doi.org/10.2174/1568009617666170208162058 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design Silica Sulfuric Acid (SSA): An Efficient and Heterogeneous Catalyst for Organic Transformations
Mini-Reviews in Organic Chemistry Role of Polyamines in Parasite Cell Architecture and Function
Current Pharmaceutical Design The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cellular and Molecular Effects of Beta Radiation from I-131 on Human Tumor Cells a Comparison with Gamma Radiation
Current Radiopharmaceuticals Inhibition of DNA Polymerase λ Suppresses 12-O-Tetradecanoylphorbol- 13-Acetate-Induced Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Bromodomain-Containing Protein 4: A Druggable Target
Current Drug Targets Improving Image Quality of Pancreatic Cancer and Surrounding Vessels with Spectral CT Imaging
Current Medical Imaging Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Alginate Based Nanocarriers for Drug Delivery Applications
Current Pharmaceutical Design Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry Thymidylate Synthase Gene in Pharmacogenetics
Current Pharmacogenomics New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Current Pharmaceutical Design